

---

## Contents

|                                                                                                                     |     |
|---------------------------------------------------------------------------------------------------------------------|-----|
| The Role of Genotyping in Pharmacological Therapy . . . . .                                                         | 1   |
| <i>K. Lindpaintner</i>                                                                                              |     |
| Pharmacogenetics and the Treatment of Cardiovascular Disease . . . . .                                              | 25  |
| <i>S.K. Tate, D.B. Goldstein</i>                                                                                    |     |
| Genetic Polymorphisms and Cardiovascular Drug Metabolism . . . . .                                                  | 39  |
| <i>A.R. Boobis, T. Shiga, R.J. Edwards</i>                                                                          |     |
| Genes That Modify Susceptibility to Atherosclerosis:<br>Targets for Drug Action . . . . .                           | 79  |
| <i>J. W. Knowles</i>                                                                                                |     |
| Lipid-Lowering Responses Modified by Genetic Variation . . . . .                                                    | 107 |
| <i>B.R. Winkelmann, M.M. Hoffmann, W. März</i>                                                                      |     |
| The Genetic Basis of Essential Hypertension and Its Implications<br>for Treatment . . . . .                         | 149 |
| <i>K.M. O'Shaughnessy, M.R. Wilkins</i>                                                                             |     |
| Genetic Predisposition to Cardiac Hypertrophy . . . . .                                                             | 177 |
| <i>A.J. Marian</i>                                                                                                  |     |
| Genetic Determinants of Susceptibility, Prognosis and Treatment<br>in Heart Failure . . . . .                       | 203 |
| <i>T. Stanton, J.M.C. Connell, J.J. V. McMurray</i>                                                                 |     |
| The Genetics of Cardiac Channelopathies: Implications for Therapeutics . . .                                        | 223 |
| <i>D.M. Roden</i>                                                                                                   |     |
| Insulin Resistance and Cardiovascular Disease: New Insights from Genetics                                           | 243 |
| <i>A. Vidal-Puig, E.D. Abel</i>                                                                                     |     |
| Genetic Disruption of Nitric Oxide Synthases and Cardiovascular Disease:<br>Lessons from a Candidate Gene . . . . . | 281 |
| <i>P.L. Huang</i>                                                                                                   |     |

Association of Thrombotic Disease with Genetic Polymorphism  
of Haemostatic Genes: Relevance to Pharmacogenetics ..... 311  
*E. G. D. Tuddenham*

The Influence of Genetic Factors on Leukocyte  
and Endothelial Cell Adhesion Molecules. .... 323  
*R. M. Rao, A. I. Russell, T. Vyse, D. O. Haskard*

Genetic Regulation of Metalloproteinase Activity:  
Pathogenic and Therapeutic Implications ..... 341  
*A. M. Henney*

Current Perspectives on Gene and Cell-Based Therapies  
for Myocardial Protection, Rescue and Repair ..... 359  
*L. G. Melo, A. S. Pachori, D. Kong, V. J. Dzau*

**Subject Index** ..... 405



<http://www.springer.com/978-3-540-40204-6>

Cardiovascular Pharmacogenetics

Wilkins, M.R. (Ed.)

2004, X, 407 p., Hardcover

ISBN: 978-3-540-40204-6